Moneycontrol PRO
Upcoming Webinar:Watch a panel of experts discuss: Challenges of continuously evolving regulation for Cryptocurrency, on 7th July at 3pm. Register Now
you are here: HomeNewsBusiness

Banks working to strengthen capital buffer to counter coronavirus-induced shocks: Report

Private banks may sell shares to raise a cumulative Rs 35,000 crore

April 30, 2020 / 11:54 AM IST

Private banks may sell shares to raise a cumulative Rs 35,000 crore to build a buffer against the economic shocks due to the coronavirus pandemic.

Bank of Baroda, RBL Bank, IndusInd Bank, Yes Bank, Kotak Mahindra Bank and IDFC First Bank are looking to build a “capital base” against the economic effects of COVID-19. RBL and IDFC First plan to raise between Rs 1,800-2,000 crore each, sources told Mint.

IDFC First Bank will reportedly use the capital for “strengthening the bank’s capital buffers further and for growth”.

Moneycontrol could not independently verify the report.

RBL Bank is also said to be looking to add growth capital and strengthen its capital position.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Follow our LIVE Updates on the coronavirus pandemic here

“The capital raising may happen when the share price goes up. The money can be used for consolidation such as acquisitions or mergers, apart from improving the bank’s tier 1 capital further," sources told the paper.

Over the past weeks, these banks have made plans to issue fresh shares to enhance common equity tier 1 (CET 1) capital, it added. CET 1 is used to measure a bank’s capability to bear loan losses and write-offs, and also measure cash reserve for acquisitions or infusions.

The lockdown to combat the spread of the virus has made it difficult for borrowers to repay loans and could increase slippages and loan write-offs in the September quarter. The second phase of the country-wide lockdown is scheduled to be lifted in phases from May 3.

Follow our full COVID-19 coverage here
Moneycontrol News
first published: Apr 30, 2020 11:51 am
ISO 27001 - BSI Assurance Mark